April 23, 2013
Corporation (NASDAQ: LIFE) today announces that it is a lead commercial partner along with
a bio-medical informatics company, in the Stratified Medicine Scotland Innovation Centre (SMS-IC). The
sequencing platform will be the primary tool to drive discovery and genetic analysis as SMS-IC aspires to be a world-class centre of research, innovation and commercialisation in stratified medicine. The SMC-IC is a unique collaboration bringing together excellence in the academic, industrial and
communities to create an infrastructure that will act as a springboard to allow
to be at the forefront of the field.
The First Minister of
has always been a world leader in innovation and this new funding for the Stratified Medicine Scotland Innovation Centre reinforces the Scottish Government's commitment to the Life Sciences securing
's place as a world leader in innovative health technology. The pioneering research carried out by the innovation centres will not only improve the healthcare of patients but also, by way of the unique advanced process of diagnosis, could potentially save lives."
"The Stratified Medicine Scotland Innovation Centre is a ground breaking project that represents a real opportunity to change the way healthcare will be practiced," said
, President Europe,
. "Life Technologies will provide facilities and the genetic analysis platform with its semiconductor based,
DNA sequencing technology, at a speed, accuracy and cost that would have been impossible just a few months ago. The vision for this project is to combine an individual's detailed genomic data with more traditional patient information to enable faster, more accurate and effective clinical decisions. This is an inflection point in the history of medical research, and there is much more to come."
Stratified medicine is recognised as a key strategic approach to the future diagnosis and treatment of disease and depends critically upon information; the integration of existing data sets to form a comprehensive 'personal' healthcare record and the generation of new data describing patient characteristics - genotype and phenotype - to permit 'stratification.'